Brii Bio joins the NIH graveyard alongside GSK, Lilly after flopping antibody study in hospitalized Covid-19 patients

Brii Bio joins the NIH graveyard alongside GSK, Lilly after flopping antibody study in hospitalized Covid-19 patients

Source: 
Endpoints
snippet: 

Just a day after GlaxoSmithKline and Vir Biotechnology’s Covid-19 antibody fell flat in an NIH-sponsored trial for hospitalized patients, researchers have ejected another therapy from the study. Is this the death knell for monoclonal antibodies for those patients?